Evidence map›Paper›PMID 36998590›Full record

ArticleNuclear medicine and molecular imaging2023

Alzheimer's Disease Prediction Using Attention Mechanism with Dual-Phase

Hyeon Kang, Do-Young Kang

Open access · hybridFull text read
In one paragraph

Article in Nuclear medicine and molecular imaging, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Hyeon KangInstitute of Convergence BioHealth, Dong-A University, Busan, Republic of Korea.ORCID https://orcid.org/0000-0001-8522-9557
Do-Young KangInstitute of Convergence BioHealth, Dong-A University, Busan, Republic of Korea.ORCID 0000-0003-1688-0818
Dong-A University · KR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Amyloid-beta (Aβ) imaging test plays an important role in the early diagnosis and research of biomarkers of Alzheimer's disease (AD) but a single test may produce Aβ-negative AD or Aβ-positive cognitively normal (CN). In this study, we aimed to distinguish AD from CN with dual-phase Materials and Methods: A total of 264 patients (74 CN and 190 AD), who underwent FBB imaging test and neuropsychological tests, were retrospectively analyzed. Early- and delay-phase FBB images were spatially normalized with an in-house FBB template. The regional standard uptake value ratios were calculated with the cerebellar region as a reference region and used as independent variables that predict the diagnostic label assigned to the raw image. Results: AD positivity scores estimated from dual-phase FBB showed better accuracy (ACC) and area under the receiver operating characteristic curve (AUROC) for AD detection (ACC: 0.858, AUROC: 0.831) than those from delay phase FBB imaging (ACC: 0.821, AUROC: 0.794). AD positivity score estimated by dual-phase FBB (R: -0.5412) shows a higher correlation with psychological test compared to only dFBB (R: -0.2975). In the relevance analysis, we observed that LSTM uses different time and regions of early-phase FBB for each disease group for AD detection. Conclusions: These results show that the aggregated model with dual-phase FBB with long short-term memory and attention mechanism can be used to provide a more accurate AD positivity score, which shows a closer association with AD, than the prediction with only a single phase FBB.

Indexed as

Alzheimer’s diseaseAmyloid-βBlood perfusionFunctional neuroimagingMachine learningNeural network

Identifiers

PMID36998590
PMCPMC10043070
OpenAlexW4290851634

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read9
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.